|Articles|November 1, 1998

Chronic Viral Hepatitis in the Era of Managed Care
Volume 4
Issue 12 Suppl

Chronic Hepatitis C: An Overview

Author(s)Jorge L. Herrera, MD

Download PDF: Chronic Hepatitis C: An Overview

Articles in this issue

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

An Overview of Viral Hepatitis

over 27 years ago

Article

Viral Hepatitis: Impact, Treatment, and Costs

over 27 years ago

Article

New Epidemiologic Data on Hepatitis B and C

over 27 years ago

Article

Appropriate Screening and Early Diagnosis of Hepatitis B and C

over 27 years ago

Article

Clinical Utility of HCV RNA Monitoring for Patients with Chronic Hepatitis C

over 27 years ago

Article

State-of-the-Art Interferon Therapy for Chronic Viral Hepatitis

over 27 years ago

Article

Cost Effectiveness of Treating Chronic Hepatitis B and C

over 27 years ago

Article

Chronic Hepatitis C: Impact, Diagnosis, and Treatment

over 27 years ago

Article

Selected Abstracts

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

Chronic Hepatitis C: An Overview

Articles in this issue

Related Content

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL

Adequate Biomarker Testing Remains Key Gap in Community Oncology Care: Urs Weber, MD